Source:http://linkedlifedata.com/resource/pubmed/id/11118001
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
12
|
pubmed:dateCreated |
2000-12-12
|
pubmed:abstractText |
There have been two previous conflicting reports that the development of T-cell-mediated autoimmune diabetes (type 1 diabetes) was respectively unaffected or inhibited in NOD mice genetically deficient in the T-helper (Th) 1 cytokine interferon (IFN)-gamma or the alpha-chain subunit of its receptor. Our goal was to resolve this conundrum by congenically transferring, from a 129 donor strain to the NOD background, a functionally inactivated gene for the beta-chain signaling (located on chromosome 16) rather than the alpha-chain ligand binding domain (located on chromosome 10) of the IFN-gamma receptor. These NOD.IFNgammaRBnull mice were characterized by normal patterns of leukocyte development and T-cells that produced greatly enhanced levels of the putatively type 1 diabetes-protective Th2 cytokine interleukin (IL)-4. However, despite being unable to respond to the primary Thl cytokine IFN-gamma and having T-cells that produce greatly enhanced levels of IL-4, NOD.IFNgammaRBnull mice remained highly susceptible to type 1 diabetes. This result indicated that the previously reported inhibition of type 1 diabetes in NOD mice carrying a functionally inactivated IFN-gamma receptor alpha-chain gene may have been due to a closely linked and previously unidentified diabetes resistance allele. Furthermore, our results indicate that the pathogenicity of diabetogenic T-cells in NOD mice is not dampened by an inability to respond to IFN-gamma and a concurrent shift to greatly enhanced Th2 cytokine production. This finding calls into question whether clinical protocols designed to shift beta-cell autoreactive T-cells from a Thl to Th2 cytokine production profile will truly be safe and efficacious in blocking the development of type 1 diabetes in humans.
|
pubmed:grant | |
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
AIM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Dec
|
pubmed:issn |
0012-1797
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
2007-11
|
pubmed:dateRevised |
2007-11-14
|
pubmed:meshHeading |
pubmed-meshheading:11118001-Animals,
pubmed-meshheading:11118001-Diabetes Mellitus, Type 1,
pubmed-meshheading:11118001-Female,
pubmed-meshheading:11118001-Gene Deletion,
pubmed-meshheading:11118001-Gene Transfer Techniques,
pubmed-meshheading:11118001-Genetic Predisposition to Disease,
pubmed-meshheading:11118001-Interleukin-4,
pubmed-meshheading:11118001-Leukocytes,
pubmed-meshheading:11118001-Male,
pubmed-meshheading:11118001-Mice,
pubmed-meshheading:11118001-Mice, Inbred NOD,
pubmed-meshheading:11118001-Protein Isoforms,
pubmed-meshheading:11118001-Receptors, Interferon,
pubmed-meshheading:11118001-Signal Transduction,
pubmed-meshheading:11118001-Th2 Cells
|
pubmed:year |
2000
|
pubmed:articleTitle |
Interferon-gamma receptor signaling is dispensable in the development of autoimmune type 1 diabetes in NOD mice.
|
pubmed:affiliation |
Jackson Laboratory, Bar Harbor, Maine 04609, USA. dvs@jax.org
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, Non-U.S. Gov't
|